Tumor cells and cancer cells in the initial developmental stages are mainly scavenged by neutrophilic leukocytes, macrophages, and other components of the primitive immune system. In 1986, Mosmann and Coffman classified CD4 ϩ T cell clones into three sub-types based on cytokine production as follows: (1) 1,2) Cytokine derived from Th-1 cells activates cytotoxic T cells mainly, and enhances delayed type hypersensitivity, while cytokine derived from Th-2 cells stimulates antibody production. The immune response is chosen depending on which sub-type of T cell is activated, which means that the proportion of the activated sub-types influences phylaxis immunity and anti-tumor immunity. This control system is also affected by the production of IL-1b, IL-12, and IL-18 by antigen presenting cells (APC). 3, 4) Recent study shows that many immune disorders are attributable to the collapse of the system controlling the proportion of Th-1 to Th-2 cells. 5) Restoration of the proper balance between Th-1 and Th-2 cells is perceived as essential in the treatment of tumors, which are generated when cellular immunity is affected by immuno-suppressing factors.
We have already reported that the D-Fraction, a b-glucan extracted from the fruiting bodies of the maitake mushroom (Grifola frondosa), activates cellular immunity and expresses anti-tumor effects. [6] [7] [8] However, the mechanism by which cytokine, the humoral factor of the immunity, provokes tumorrejection during the anti-tumor action of D-Fraction, remained to be investigated. In this study, we investigated the change in the proportion of Th-1/Th-2 cells when maitake mushroom D-Fraction expresses its anti-tumor effects, and also how the cytokines are involved in the mechanism. Antibodies The following monoclonal antibodies were purchased from Pharmingen Co.: CD16/CD32 (0.5 mg/ml), FITC-conjugated CD8 (0.5 mg/ml), FITC-conjugated CD69 (0.5 mg/ml), FITC-conjugated IFN-g (0.5 mg/ml), R-PEconjugated IL-4 (0.2 mg/ml), R-PE-conjugated CD19 (0.2 mg/ml), R-PE-conjugated CD69 (0.2 mg/ml), Cy-Chrom TM -conjugated CD3e (0.2 mg/ml), and Cy-Chrom TM -conjugated CD4 (0.2 mg/ml).
MATERIALS AND METHODS

Materials
Animals Male C3H/HeN mice (4 weeks old) were provided by Japan Clea Co. (Osaka, Japan) and were raised for one week before being used for experiments.
The D-Fraction was prepared from the dried powder according to a method described previously.
9)
Dosage of D-Fraction MM-46 carcinoma cells (2ϫ10 6 ) were implanted in 8 male mice of the C3H/HeN strain (5 weeks old) in the right axillary region. After 24 h, the DFraction (5 mg · kg Ϫ1 · d
Ϫ1
) was administered to the MM-46 carcinoma-bearing mice intraperitoneally (i.p.) for 19 consecutive days. As a control, phosphate buffered saline (PBS) was also injected for 19 consecutive days. This trial was done 3 times, and the same results were obtained each time.
Preparation of Whole Spleen Cells On day 20 in mice administered D-Fraction or PBS, the spleen was extirpated from any 2 mice in 5 mice of the treated group, passed through nylon mesh (f70 mm), and washed with RPMI-1640 medium by centrifugation (300ϫg, 5 min, 4°C). The precipitated cells were collected and hemolyzed to remove erythrocytes. After the centrifugation, the precipitated cells were washed with RPMI-1640 medium and suspended in RPMI-1640 medium containing 10% fetal bovine serum (FBS).
Preparation of Lymph Node Cells On day 20 after the administration of D-Fraction or PBS, the inguinal lymph node was extirpated from any 2 mice in 5 mice of the treated group, passed through nylon mesh, and washed with RPMI-1640 medium by centrifugation (300ϫg, 5 min, 4°C). The precipitated cells were collected and suspended in RPMI-1640 medium containing 10% FBS.
Preparation of Peritoneal Macrophages On day 20 after the administration of D-Fraction or PBS, 3 mice were killed by vertebral dislocation, and the cells were obtained by washing the peritoneal cavity with RPMI-1640 medium. After centrifugation (300ϫg, 5 min, 4°C), the precipitated cells were suspended in RPMI-1640 medium containing 10% FBS. After cultivation, adherent cells were collected.
Determination of Cytokine Release by ELISA One times 10 5 cells/well of whole spleen cells or lymph node cells obtained from 3 mice in 5 mice of the treated group were cultured in a 96-well plate with Con A (final concentration, 10 mg/ml) at 37°C for 24 h in 5% CO 2 . After the stimulation, the culture supernatant (100 ml) was collected by centrifugation (300ϫg, 5 min), and levels of IL-12 p70, IL-18, and TNF-a were determined by ELISA. IL-1b in the culture supernatant of peritoneal macrophages (1ϫ10 5 cells/well) without Con A was also determined by ELISA.
Flow Cytometry
10)
For cell-surface antigen detection, 100 ml of the whole spleen cells or lymph node cells (1ϫ10 For intracellular cytokine detection, 1 ml of the whole spleen cells or lymph node cells (2ϫ10 6 cells/ml) was applied to a 24-well plate, ionomycin (750 ng/ml ) and phorbol-12-myristate-13-acetate (50 ng/ml) were added to each well, and the plate was incubated with 1.4 ml of Goldi Stop at 37°C in 5% CO 2 for 4 h. After the stimulation, 0.5 ml of anti CD16/CD32 monoclonal antibody was added and reacted at 4°C for 5 min. Then, each Cy-Chrome TM -conjugated CD4 monoclonal antibody (mAbsм1 mg) was reacted at 4°C for 20 min. After the reaction, the cells were washed with Staining Buffer (0.09% NaN 2 and 2% FBS in PBS), incubated with 100 ml of Cytofix/Cytoperm at 4°C for 20 min, and washed again with Perm/Wash. The stained cells were reacted with each of the FITC-conjugated IFN-g monoclonal antibodies (0.2 mg) and R-PE-conjugated IL-4 monoclonal antibodies (0.1 mg) for CD4 ϩ T cells at 4°C for 30 min, then washed with Perm/Wash, suspended in 0.5 ml of Staining Buffer, and counted by FACScan TM . Cells were obtained from any 3 mice in 5 mice of the treated group.
Statistical Analysis Values are expressed as the meanϮ S.E.M, and differences between the control mice and the DFraction-administered mice were examined using Student's ttest.
RESULTS
Activation of T Cells and B Cells
As shown in Fig. 1 , relative to the control mice, the D-Fraction-administered mice exhibited a tumor inhibition rate (T.I.R.) of 82%. The significant inhibition by D-Fraction was presumed to activate lymphocytes which enhance anti-tumor immunity. We investigated, therefore, the activation of T cells and B cells in the whole spleen and in the lymph node of the inguinal region of D-Fraction-administered mice bearing MM-46 carcinoma for 20 d. The target for detection was CD3e ϩ in the T cells, and CD19 ϩ in the B cells, surface antigens of the respective cell populations. CD69 is known to be the early activation marker on CD4 ϩ T cells, CD8 ϩ T cells and B cells, in addition to macrophages and NKT cells. 11) To study the activation of these cells, we also determined the expression ratio of CD69 by flow cytometric analysis. As shown in Fig. 2A , there was no effect on B cell or T cell activation by D-Fraction in the whole spleen cells. In the inguinal lymph node, however, CD69 expression in T cells increased compared with the control mice (Fig. 2B) . On the other hand, CD69 expression in B cells decreased. Rates of activated T cell/B cell increased 2-fold in the D-administered mice. These results suggest that D-Fraction inhibits the introduction into the tumor area of B cells which produce antibodies, but activates T cells and stimulates cellular immunity.
Activation of T Cell Subsets
To clarify which of the T cell subsets contributes to the cellular immunity, we prepared CD4 ϩ cells and CD8 ϩ cells as targets because they are the surface antigens for helper T cells (Th) and cytotoxic T cells (CTL), respectively. As shown in Fig. 3 , in the inguinal lymph node, CD69 expression in CD4 ϩ cells increased com- ϩ among the T cell subsets.
IFN-g g or IL-4 Expression in CD4
؉ T Cells Th cells are classified into two sub-types, Th-1 cells which produce IL-2 and IFN-g and stimulate cellular immunity, and Th-2 cells which release IL-4, IL-5, IL-6, and IL-10 and activate humoral immunity. 1, 2) As the cytokines produced by these two sub-types have different immunological activities, the balance between the two is considered to be important to antitumor immunity. Therefore, we investigated the cytokines expressed in the CD4 ϩ T cells. We analyzed the IFN-g and IL-4 expression ratio in the CD4 ϩ T cells using flow cytometry by setting up a lymphocyte gate for whole spleen cells and inguinal lymph node cells, and also a gate for CD4 ϩ cells (Fig. 4) . The productivity ratio for IFN-g increased 1.4-fold compared with the control value, while that for IL-4 was unchanged. The expression ratio of IL-4 in the inguinal lymph node cells was 0.7 for D-administered mice. The expression ratio of IFN-g was increased at 1.6-fold.
This result was obtained by using of any 3 mice in 5 mice of the treated group.
IL-12 and IL-18 Production by Whole Spleen Cells and Lymph Node Cells On tumor initiation, various cytokines are released from immuno-competent cells, other than from CD4
ϩ T cells. To confirm this, we investigated IL-12 p70, IL-18, IL-1b and TNF-a, which would affect the Th-1/Th-2 population. Whole spleen cells and inguinal lymph node cells were stimulated by cultivation for 24 h, and the cytokines in the culture supernatant were measured by ELISA. In both populations of cells, the production of IL-12 p70 increased significantly compared with the control (Fig. 5A) . IL-12, which is released from Th-1 cells, is an important cytokine that promotes cellular immune reactions, and stimulates IFN-g productivity in T cells.
12) IL-12 p70 production increased because D-Fraction activated immunity in the dominant Th-1 population. As shown in Fig. 5B , D-Fraction increased IL-18 production in the whole spleen cells by 1.7-fold, and in the inguinal lymph node cells by 4.7-fold compared with the control. IL-18 strongly induces the production of IFN-g by T cells and B cells. 13) Insert T cells do not respond to IL-12 or IL-18, but when primed by a carcinoma antigen, the cells become responsive to IL-12 or IL-18 and produce IFN-g. The amount of IL-1b in the supernatant obtained from peritoneal macrophages cultured for 24 h was examined. As shown in Fig. 6 , a marked decrease in IL-1b was observed in the D-Fraction-administered mice, to 0.4 of the control. IL-1b is an inflammatory cytokine produced mostly by antigen presenting cells such as macrophages, and acts as a secondary stimulant for Th-2 activation. Mouse Th-1 cells do not express IL-1b receptors, therefore, the cells are not affected by this cytokine.
14) The decrease in IL-1b production indicates that D-Fraction inhibited the stimulation of Th-2 cells. Figure 7 shows TNF-a production by whole spleen cells. D-Fraction-administered mice exhibited a 2.5-fold increase in production compared with the control. TNF-a is a cytokine mainly produced by macrophages, and has various functions in relation to inflammatory and cytotoxic reactions, as well as cytotoxicity, and directly causes hemor- ϩ cells. The CD4 ϩ T cells are classified into two sub-types based on cytokine production, that is, Th-1 cells which produce IL-2, IFN-g and TNF-b, and evoke cellular immunity, and Th-2 cells which produce IL-4, IL-5, IL-6, L-10, and IL-13, and stimulate humoral immunity. The balance between these two sub-types is presumed essential to phylaxis immunity, anti-tumor immunity, etc. To verify this, flow cytometry was used to obtain an expression ratio of two intracellular cytokines, IFN-g and IL-4 in CD4 ϩ T cells. The results indicate that IFN-g expression increased and IL-4 expression decreased when D-Fraction was administered to tumor-bearing mice. This suggests that D-Fraction established Th-1 dominance in a T cell population which was once Th-2 dominant due to carcinoma. In addition, an investigation was also made on IL-12 p70 and IL-18, the cytokines controlling the Th-1/Th-2 balance. IL-12 is a heterodimer of P35 and P40, 13, 14) and activates macrophages and NK cells by promoting immune responses directed by Th-1. IL-18, formerly known as IGIF (IFN-g inducing factor), 15, 16) cooperates with IL-12 to strongly promote the production of IFN-g by T cells, and B cells, and also enhances the functions of Th-1 cells as well as promoting the expression of Fas ligand. 13, 14) However, recent findings show that IFN-g is produced only when IL-12 coexists with IL-18; otherwise, T cells, basofilic leukocytes, mastcytes, etc. are acted upon, and Th-2 cytokines such as IL-4/IL-13 are produced in vitro. 17) In addition, IL-18 stimulates CD4 ϩ T cells in vitro and induces the production of IgE dependent on IL-4. 18) In this investigation, we found that production of IL-12 p70 and IL-18 was enhanced in whole spleen cells and in the inguinal lymph node, which suggests that D-Fraction evokes Th-1-dominant immune reactions even in carcinoma-bearing mice. This result also explains why the production of IFN-g was enhanced by D-Fraction. It also suggests that the Th-1/Th-2 population became Th-1 dominant owing to the inhibition of IL-1b production in peritoneal macrophages by the effect of D-Fraction. As stated above, D-Fraction can be used to control the balance between Th-1 and Th-2 cells. However, the mechanism by which naive cells (Th-0) achieve functional conversion to become Th-1 or Th-2 cells is yet to be clarified. Th-1 cells have the ability to change temporarily into Th-2 cells, but mature Th-2 cells cannot change back. This is because Th-1 cells are affected by IL-4 signals even after attaining maturity, but Th-2 cells, when mature, do not recognize IL- 12 signals. 19) Therefore, the function of D-Fraction in establishing Th-1 dominance is not the changing of mature Th-2 into Th-1 cells, but more likely either the enhancement of conversion of naive cells, i.e. Th-0 into Th-1 cells, or the inhibition of conversion of Th-1 into Th-2 cells.
In summary, the maitake D-Fraction induces the onset of immunity dominated by Th-1 cells converted from Th-0 cells, and consequently stimulates cellular immunity, and expresses anti-tumor effects.
